Products
Latest News
FAQ
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .
Phase 2
Withdrawn
Conditions
Metastatic Triple Negative Breast Cancer
Interventions
Drug: Sabizabulin
Drug: Sabizabulin/Sacituzumab govitecan-hziy Combo
Drug: Sacituzumab Govitecan-hziy
Subscribe
First Posted Date
2021-08-17
Last Posted Date
2022-02-08
Lead Sponsor
Veru Inc.
Registration Number
NCT05008510
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy